The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies

References

• Barlogie B, Hall R, Zander A, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298–1301.
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493–1498.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Dicke KA, Armitage JO, et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986;104:163–168.
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91–97.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988;71:723–727.
   PubMed Web of Science ®Google Scholar
• Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor. effects on normal and leukemic myeloid cells. Science 1986;232:61–65.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Anderson JR, Jackson JD, et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994;83:610–616.
   PubMed Web of Science ®Google Scholar
• Pulsipher MA, Chitphakdithai P, Logan BR, et al. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood 2014;123:3655–3663.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353–357.
   PubMed Web of Science ®Google Scholar
• Siena S, Schiavo R, Pedrazzoli P, et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;18:1360–1377.
   PubMed Web of Science ®Google Scholar
• To LB, Dyson PG, Juttner CA. Cell-dose effect in circulating stem-cell autografting. Lancet 1986;2:404–405.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Bregni M, Siena S, et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?Hematol Oncol 1989;7:139–148.
   PubMed Web of Science ®Google Scholar
• Stella CC, Cazzola M, De Fabritiis P, et al. CD34-positive cells: biology and clinical relevance. Haematologica 1995;80:367–387.
   PubMed Web of Science ®Google Scholar
• Krause DS, Fackler MJ, Civin CI, et al. CD34: structure, biology, and clinical utility. Blood 1996;87:1–13.
   PubMed Web of Science ®Google Scholar
• Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991;77:400–409.
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787–3794.
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997;90:2939–2951.
   PubMed Web of Science ®Google Scholar
• Kiss JE, Rybka WB, Winkelstein A, et al. Relationship of CD34 + cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997;19: 303–310.
   PubMed Web of Science ®Google Scholar
• van der Wall E, Richel DJ, Holtkamp MJ, et al. Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol 1994;5:795–802.
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547–2555.
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588–596.
   PubMed Web of Science ®Google Scholar
• Klaus J, Herrmann D, Breitkreutz I, et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007;78:21–28.
   PubMed Web of Science ®Google Scholar
• Dercksen MW, Rodenhuis S, Dirkson MK, et al. Subsets of CD34 + cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995;13:1922–1932.
   PubMed Web of Science ®Google Scholar
• Klumpp TR, Goldberg SL, Magdalinski AJ, et al. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment. Bone Marrow Transplant 1997;20:273–281.
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delarue R, Somme D, et al. High-dose CD34 + cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion 2002;42:443–450.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dreger P, Zander AR, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:261–266.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Micallef I, Nademanee AP, et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011;17:1146–1153.
   PubMed Web of Science ®Google Scholar
• Ninan MJ, Flowers CR, Roback JD, et al. Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant 2007;13:895–904.
   PubMed Web of Science ®Google Scholar
• Bolwell BJ, Pohlman B, Rybicki L, et al. Patients mobilizing large numbers of CD34 + cells (“super mobilizers”) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007;40:437–441.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003;44:815–820.
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;37:719–724.
   PubMed Web of Science ®Google Scholar
• Raschle J, Ratschiller D, Mans S, et al. High levels of circulating CD34 + cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma. Br J Cancer 2011;105: 970–974.
   PubMed Web of Science ®Google Scholar
• Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012;19: 324–335.
   PubMed Web of Science ®Google Scholar
• Pavletic ZS, Joshi SS, Pirruccello SJ, et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998;21:33–41.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001;98:579–585.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002;117:629–633.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:291–298.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Gertz MA, Geyer SM, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004;18:1085–1092.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Sohn BS, Jang G, et al. Higher infused CD34 + hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009;49:1890–1900.
   PubMed Web of Science ®Google Scholar
• Gordan LN, Sugrue MW, Lynch JW, et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 2003;31:1009–1013.
   PubMed Web of Science ®Google Scholar
• Kim H, Sohn HJ, Kim SE, et al. Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;34:43–49.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Hiwase S, Bailey M, et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008;14:116–124.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008;14:807–816.
   PubMed Web of Science ®Google Scholar
• Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant 2009;15: 765–776.
   PubMed Web of Science ®Google Scholar
• Venstrom JM, Zheng J, Noor N, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res 2009;15:7330–7334.
   PubMed Web of Science ®Google Scholar
• Lizee G, Radvanyi LG, Overwijk WW, et al. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res 2006;12:4794–4803.
   PubMed Web of Science ®Google Scholar
• Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002;110:185–192.
   PubMed Web of Science ®Google Scholar
• Romero Fernandez E, Bravo GM, Gallastegui RA, et al. Lymphocyte recovery and infused CD34 + cells dose. Effect on the evolution after stem cell autotransplantation. Leuk Res Rep 2013;2:54–57.
   Google Scholar
• Blystad AK, Delabie J, Kvaloy S, et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004;125:605–612.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Chao N, Shapiro J, et al. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. Biol Blood Marrow Transplant 2013;19: 1301–1309.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720–5726.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767–4773.
   PubMed Web of Science ®Google Scholar
• Farina L, Spina F, Guidetti A, et al. Peripheral blood CD34 + cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor. an algorithm for the pre-emptive use of plerixafor. Leuk Lymphoma 2014;55:331–336.
   PubMed Web of Science ®Google Scholar
• Humpe A, Buwitt-Beckmann U, Schub N, et al. Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis. Transfus Med Hemother 2013;40:251–257.
   PubMed Web of Science ®Google Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol 2014;164:113–123.
   PubMed Web of Science ®Google Scholar
• Desikan KR, Barlogie B, Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998;16:1547–1553.
   PubMed Web of Science ®Google Scholar
• Narayanasami U, Kanteti R, Morelli J, et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059–2064.
   PubMed Web of Science ®Google Scholar
• Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009;84:335–337.
   PubMed Web of Science ®Google Scholar
• Basak GW, Jaksic O, Koristek Z, et al.; Central, Eastern European Leukemia Group. Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 2011;86:550–553.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Alexander ET, Hogan KR, et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64–69.
   PubMed Web of Science ®Google Scholar
• Chen AI, Bains T, Murray S, et al. Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization. Bone Marrow Transplant 2012;47:1526–1529.
   PubMed Web of Science ®Google Scholar
• Shaughnessy P, Islas-Ohlmayer M, Murphy J, et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011;17:729–736.
   PubMed Web of Science ®Google Scholar
• Vishnu P, Roy V, Paulsen A, et al. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012;52:55–62.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2013;19:87–93.
   PubMed Web of Science ®Google Scholar
• Mariette X, Fermand JP, Brouet JC. Myeloma cell contamination of peripheral blood stem cell grafts in patients with multiple myeloma treated by high-dose therapy. Bone Marrow Transplant 1994;14:47–50.
   PubMed Web of Science ®Google Scholar
• Ladetto M, Donovan JW, Harig S, et al. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000;6:241–253.
   PubMed Web of Science ®Google Scholar
• McCann JC, Kanteti R, Shilepsky B, et al. High degree of occult tumor contamination in bone marrow and peripheral blood stem cells of patients undergoing autologous transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996;2:37–43.
   PubMedGoogle Scholar
• Olsson K, Gerard CJ, Zehnder J, et al. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD). Leukemia 1999;13:1833–1842.
   PubMed Web of Science ®Google Scholar
• Moos M, Schulz R, Cremer F, et al. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 1995;13(Suppl. 3):42–51.
   PubMed Web of Science ®Google Scholar
• Jacquy C, Soree A, Lambert F, et al. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 2000;110:631–637.
   PubMed Web of Science ®Google Scholar
• Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749–755.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525–1533.
   PubMed Web of Science ®Google Scholar
• Preijers FW, De Witte T, Wessels JM, et al. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989;74:1152–1158.
   PubMed Web of Science ®Google Scholar
• Jones RJ. Purging with 4-hydroperoxycyclophosphamide. J Hematother 1992;1:343–348.
   PubMedGoogle Scholar
• Martin-Henao GA, Picon M, Amill B, et al. Isolation of CD34 + progenitor cells from peripheral blood by use of an automated immunomagnetic selection system: factors affecting the results. Transfusion 2000;40:35–43.
   PubMed Web of Science ®Google Scholar
• Schumm M, Lang P, Taylor G, et al. Isolation of highly purified autologous and allogeneic peripheral CD34 + cells using the CliniMACS device. J Hematother 1999;8:209–218.
   PubMedGoogle Scholar
• Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325–3333.
   PubMed Web of Science ®Google Scholar
• van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003;102:3521–3529.
   PubMed Web of Science ®Google Scholar
• Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002;100:1559–1565.
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Forman SJ. Graft purging in autologous bone marrow transplantation: a promise not quite fulfilled. Oncology (Williston Park) 2004;18:867–876; discussion 876–868, 881, 884.
   PubMed Web of Science ®Google Scholar
• Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918–3927.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001;19:3771–3779.
   PubMed Web of Science ®Google Scholar
• Hahn T, Wingard JR, Anderson KC, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 2003;9:4–37.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011;17:20–47 e30.
   PubMed Web of Science ®Google Scholar
• Oliansky DM, Gordon LI, King J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010;16:443–468.
   PubMed Web of Science ®Google Scholar
• Varmavuo V, Mantymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012;89:128–135.
   PubMed Web of Science ®Google Scholar
• Sheng L, Fu S, Hu Y, et al. Rapid mobilization of fully functional natural killer cells into blood by AMD3100. Transfusion 2013;53: 2108–2110.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Markovic SN. Autograft mediated adoptive immunotherapy of cancer in the context of autologous stem cell transplantation. World J Clin Oncol 2010;1:29–34.
   PubMedGoogle Scholar
• Ansell K, Porrata LF. Autograft monocytes: the bad humors of autologous peripheral blood hematopoietic stem cell transplantation. J Stem Cell Res Ther 2013;(S3):005.
   Google Scholar
• Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 2013;31:1662–1668.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012;30:4462–4469.
   PubMed Web of Science ®Google Scholar